Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Clinical evidence

RIZE

59 evidence topics · 7 sources

Objective
Location and study date
Study dates in the trial registry
MilestoneQuoted date
Study start (actual)“2020-02-24”
Primary completion (actual)“2022-04-05”
Study completion (actual)“2022-08-19”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent time in glucose target range 70-180 mg/dL by continuous glucose monitoring as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the trial registry
MilestoneCohort 1, 3 mg/kgCohort 2, 6 mg/kgCohort 3, 9 mg/kgCohort 4, 3 to 9 mg/kg
Started“4”“8”“8”“3”
Completed“4”“8”“8”“3”
Not completed“0”“0”“0”“0”
Baseline characteristics
Demographics and baseline disease characteristics, intention-to-treat population
ParameterCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 8)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 23)
Age in years, mean (range)“5.8 (2–12)”“9.3 (2–22)”“5.8 (2–17)”“4.0 (2–6)”“6.7 (2–22)”
Male, n“4”“5”“3”“1”“13 (57%)”
KATP channel mutation, n“1”“5”“4”“1”“11 (48%)”
Unknown genetic etiology“3”“2”“3”“1”“9 (39%)”
Congenital HI therapy, n (%)“4”“7”“6”“3”“20 (87%)”
Diazoxide“2”“3”“1”“2”“8 (35%)”
Somatostatin analog (long acting/short acting)“2/0”“2/2”“3/3”“1/0”“8/5 (52%)”
Enteral or tube use“0”“2”“3”“0”“5 (22%)”
Pancreatectomy“0”“0”“3”“1”“4 (17%)”
History of seizure, n“4”“4”“5”“3”“16 (70%)”
Hospitalization within the past year, n“3”“3”“6”“2”“14 (61%)”
Percent time in range (70–180 mg/dL) by CGM, mean (range)“82 (74–89)”“74 (66–89)”“71 (12–90)”“68 (57–87)”“74 (12–90)”
Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range)“16 (11–22)”“22 (11–32)”“24 (6–88)”“29 (11–42)”“23 (6–88)”
Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range)“8 (1–13)”“16 (4–52)”“15 (7–29)”“8 (4–11)”“13 (1–52)”
Sex, race, and country of enrollment in the trial registry results
CharacteristicQuoted total (n = 23)
Female“13”
Male“10”
White“20”
Enrolled in Turkey“7”
Enrolled in Russia“5”
Enrolled in Bulgaria“3”
Efficacy results
Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population
MeasureCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 22)
Median daily percent time in range at baseline“81.7”“72.9”“83.4”“59.3”“76.9”
Median daily percent time in range at week 8“84.8”“78.5”“82.9”“70.8”“79.1”
Median percent change from baseline“6.19”“0.31”“5.52”“9.07”“4.59”
Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population
MetricCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled, median (range)
Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline“10.1”“12.5”“13.0”“9.3”“11.5 (4.0–52.0)”
Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment“9.9”“6.6”“1.9”“7.6”“5.0 (0–23.8)”
Hypoglycemia events (<70 mg/dL), % change from baseline (p value)“−1.6 (NS)”“−48 (0.016)”“−84 (0.016)”“−19.9 (NS)”“−59 (<0.001)”
Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value)“−40 (NS)”“−78 (NS)”“−100 (0.016)”“−27 (NS)”“−78 (0.005)”
Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline“16.3”“20.3”“13.7”“34.4”“16.2 (6–88)”
Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment“12.3”“6.7”“5.4”“20.4”“8.5 (0.3–34)”
Time in hypoglycemia (<70 mg/dL), % change from baseline (p value)“−31 (NS)”“−65 (0.023)”“−61 (0.016)”“−47 (NS)”“−54 (<0.001)”
Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value)“−22 (NS)”“−74 (NS)”“−85 (NS)”“−61 (NS)”“−65 (NS)”
Overnight hypoglycemia and time above range, per-protocol population
EndpointCohort 1, 3 mg/kgCohort 2, 6 mg/kgCohort 3, 9 mg/kgCohort 4, 3 to 9 mg/kgPooled
Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value)“−15.8 (NS)”“−54.8 (NS)”“−55.0 (NS)”“−61.9 (NS)”“−52.2 (0.006)”
Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value)“−15.5 (NS)”“−49.3 (NS)”“−42.9 (NS)”“−56.5 (NS)”“−40.7 (0.04)”
Percent time above range (>180 mg/dL) by CGM, net change“+0.53”“+6.7”“+9.4”“+10.4”“+6.03”
Average overnight glucose (mg/dL) by CGM, net change“−2.5”“+21.5”“+19.3”“+19.8”“+17.8”
Fasting challenge in the trial registry
MeasureCohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 7)Cohort 4, 3 to 9 mg/kg (n = 3)Pooled (n = 22)
Participants able to complete fast at baseline“3”“2”“0”“0”“5”
Participants able to complete fast at end of treatment“3”“1”“2”“1”“7”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overview of treatment-emergent adverse events, safety population
CategoryPre-treatment non-TEAE, total (n = 23)Cohort 1, 3 mg/kg (n = 4)Cohort 2, 6 mg/kg (n = 8)Cohort 3, 9 mg/kg (n = 8)Cohort 4, titrate (n = 3)Ersodetug, total (n = 23)
Participants with adverse events, n (%)“10 (43)”“2 (50)”“7 (88)”“5 (63)”“2 (67)”“16 (70)”
Participants with serious adverse events, n (%)“0 (0)”“0 (0)”“2 (25)”“1 (13)”“0 (0)”“3 (13)”
Participants with investigator-judged study drug-related adverse events, n (%)“2 (9)”“0 (0)”“2 (25)”“1 (13)”“0 (0)”“3 (13)”
Participants with grade 3 (severe) adverse events, n (%)“1 (4)”“0 (0)”“2 (25)”“0 (0)”“0 (0)”“2 (9)”
Participants with grade 4 (life threatening) adverse events, n (%)“0 (0)”“0 (0)”“0 (0)”“1 (13)”“0 (0)”“1 (4)”
Study limitations
Summary
  • Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
  • Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
  • Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
  • Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.